Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cytokinetics, Incorporated - Common Stock (NQ:CYTK)

70.71 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cytokinetics, Incorporated - Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
News headline image
Cytokinetics AdComm Outcome Might Be Blessing In Disguise, This Analyst Said ↗
 
Via Benzinga
News headline image
REV Group, Avidity Biosciences And Some Other Big Stocks Moving Higher On Wednesday ↗
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Why Cytokinetics Is Soaring After A 'Bruising' FDA Meeting For Its Heart Drug ↗
The FDA's experts voted 3-8 against the Cytokinetics heart-failure drug. 
Via Investor's Business Daily
News headline image
Top Stories Today: Jack Dorsey Not Exactly Impressed With Elon Musk's Twitter; Binance Sees $3B Outflow In 7 Days.. ↗
Benzinga 
Via Benzinga
News headline image
FDA Adcomm Gives Thumbs Down To Cytokinetics' Heart Failure Candidate ↗
 
Via Benzinga
News headline image
Where Cytokinetics Stands With Analysts ↗
Cytokinetics (NASDAQ:CYTK) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Analyst Ratings for Cytokinetics ↗
Cytokinetics (NASDAQ:CYTK) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors ↗
Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%. 
Via Benzinga
News headline image
Cytokinetics CEO: Why It's OK Not Being An Overnight Success ↗
The company hopes to come out next year with at least one heart-failure drug. 
Via Investor's Business Daily
News headline image
Coca-Cola Price Target Cut By This Analyst? Plus Rocket Pharmaceuticals Likely To Rally Around 306% ↗
Wells Fargo cut the price target on The Coca-Cola Company (NYSE: KO) from $72 to $66. Wells Fargo analyst Chris Carey maintained an Overweight rating on the stock. Coca-Cola shares rose 0.3% to $56.20... 
Via Benzinga
News headline image
Swing Trading Stock Watchlist For The Week Of Sept. 6 ↗
The overall stock market health is poor. I created a watchlist this week mainly to see how many stocks were forming quality contraction or cup-and-handle patterns. Let's take a look. 
Via Talk Markets
News headline image
Where Cytokinetics Stands With Analysts ↗
Within the last quarter, Cytokinetics (NASDAQ:CYTK) has observed the following analyst ratings: 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Why Allena Pharmaceuticals Tumbled Over 30%; Here Are 85 Biggest Movers From Yesterday ↗
Gainers Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) shares jumped 91.3% to close at $28.50 on Tuesday amid post-IPO volatility. 
Via Benzinga
News headline image
iRobot, Fox Factory, TripAdvisor And Some Other Big Gainers From Friday ↗
U.S. stocks closed mixed on Friday following the release of jobs data for July. Here is the list of some big stocks moving higher in the previous session. 
Via Benzinga
News headline image
What 5 Analyst Ratings Have To Say About Cytokinetics ↗
Analysts have provided the following ratings for Cytokinetics (NASDAQ:CYTK) within the last quarter: 
Via Benzinga
News headline image
Cytokinetics Records $89M Q2 Sales On Deferred Mavacamten Revenues, Forecasts FY22 Cash Of Over $800M ↗
 
Via Benzinga
News headline image
Recap: Cytokinetics Q2 Earnings ↗
Cytokinetics (NASDAQ:CYTK) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Cytokinetics beat estimated... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Gainers 
Via Benzinga
News headline image
The Daily Biotech Pulse: European Backing For Novavax's COVID-19 Shot In Adolescents, Sanofi-GSK's Updated Vaccine Effective Against Omicron, FDA's Clinical Hold On Sarepta's Duchenne Trial ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
What 5 Analyst Ratings Have To Say About Cytokinetics ↗
Within the last quarter, Cytokinetics (NASDAQ:CYTK) has observed the following analyst ratings: 
Via Benzinga
Revenues From Treatment of Rare Neurological Disorders Worldwide Are Poised to Surpass $12 Billion in 2026
Palm Beach, FL – June 22, 2022 – FinancialNewsMedia.com News Commentary Neuroinflammatory disorder is the study of conditions where immune responses which damage components of the nervous system. It... 
Via FinancialNewsMedia
News headline image
The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More ↗
Biotech stocks advanced in the week ending May 22, defying the broader market retreat. The defensive nature of the industry and stock-specific moves lent support. 
Via Benzinga
News headline image
Top Biotech Stocks: Trading Opportunities For Next Week - Sunday, May 22 ↗
A security pattern traces the distinct movements of security prices that, once recognized, help traders to make informed trading decisions. Let's look at some biotech stock opportunities by analyzing... 
Via Talk Markets
Why Orphan Drug Designation Offers Several Benefits
Palm Beach, FL – May 18, 2022 – FinancialNewsMedia.com News Commentary – The U.S. FDA prioritizes developing new treatments for rare diseases with the ability to grant Orphan Drug Designation. Here we... 
Via FinancialNewsMedia
News headline image
The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
10 Biggest Price Target Changes For Monday ↗
Needham cut the price target on Carvana Co. (NYSE: CVNA) from $121 to $80. Carvana shares rose 11.3% to $42.71 in pre-market trading. 
Via Benzinga
News headline image
Cytokinetics: Q1 Earnings Insights ↗
Cytokinetics (NASDAQ:CYTK) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Cytokinetics missed estimated... 
Via Benzinga
News headline image
70 Biggest Movers From Friday ↗
Gainers GTY Technology Holdings Inc. (NASDAQ: GTYH) shares climbed 115.2% to close at $6.09 as the company agreed to be acquired by GI Partners. Vaxxinity, Inc. (NASDAQ: VAXX)... 
Via Benzinga
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.